

Anderson et al. - U.S. Patent Appl. No. 09/576,424

II. CLAIM AMENDMENTS

1-10. (Canceled)

11. (Previously Presented) A method for inhibiting or preventing T cell/B cell interactions associated with Crohn's disease comprising administering an amount of a monoclonal anti-CD80 antibody or a CD80-binding fragment thereof sufficient to inhibit the binding of B cells and T cells via the CD80/CD28 pathway; wherein said monoclonal antibody or fragment thereof binds specifically to CD80 antigen without inhibiting the binding of CD80 antigen to CTLA-4.

12. (Currently Amended) The method of Claim 11, wherein said anti-CD80 antibody is a human monoclonal antibody, or a chimeric or humanized antibody comprising ~~variable regions of a non-human anti-CD80 antibody and human~~ constant regions derived from human constant regions.

13-18. (Canceled)

19. (Previously Presented) The method of Claim 11, wherein said anti-CD80 antibody competes for binding to CD80 antigen with antibody 7C10, produced by a hybridoma assigned ATCC accession no. HB-12117, or antibody 16C10, produced by a hybridoma assigned ATCC accession no. HB-12119.

20. (Previously Presented) The method of Claim 12, wherein said anti-CD80 antibody is a chimeric antibody comprising variable regions of an Old World monkey antibody and human constant regions.

21-26. (Canceled)

27. (Previously Presented) A method of treating Crohn's disease in a subject in need of such treatment by administering a therapeutically effective amount of a monoclonal anti-CD80 antibody or a CD80-binding fragment thereof that does not inhibit the CD80/CTLA-4 binding interaction.

28. (Currently Amended) The method of Claim 27, ~~comprising administering wherein said anti-CD80 antibody is~~ a human monoclonal anti-CD80 antibody, or a chimeric or humanized antibody comprising ~~variable regions of a non-human anti-CD80 antibody and human~~ constant regions derived from human constant regions.

Anderson et al. - U.S. Patent Appl. No. 09/576,424

29. (Previously Presented) The method of Claim 28, comprising administering a chimeric anti-CD80 antibody comprising variable regions of an Old World monkey antibody and human constant regions.

30. (Previously Presented) The method of Claim 11, wherein said anti-CD80 antibody or CD80-binding fragment thereof is administered in combination with an immunomodulator selected from the group consisting of IL-7, IL-10, CTLA4-Ig, soluble CTLA-4, an anti-CD28 antibody, and a CD28-binding fragment of an anti-CD28 antibody.

31. (Previously Presented) The method of Claim 27, wherein said anti-CD80 antibody or CD80-binding fragment thereof is administered in combination with an immunomodulator selected from the group consisting of IL-7, IL-10, CTLA4-Ig, soluble CTLA-4, an anti-CD28 antibody, and a CD28-binding fragment of an anti-CD28 antibody.

32. (Currently Amended) The method of Claim 11, wherein said anti-CD80 antibody or CD80-binding fragment thereof is administered in combination with an immunosuppressant selected from the group consisting of cyclosporin A, FK506, anti-TNF α antibody, anti-CD54 antibody, anti-CD11 antibody, anti-CD11a antibody, anti-IL-1 antibody, TNF α receptor, and IL-1 receptor.

33. (Currently Amended) The method of Claim 27, wherein said anti-CD80 antibody or CD80-binding fragment thereof is administered in combination with an immunosuppressant selected from the group consisting of cyclosporin A, FK506, anti-TNF α antibody, anti-CD54 antibody, anti-CD11 antibody, anti-CD11a antibody, anti-IL-1 antibody, TNF α receptor, and IL-1 receptor.

34. (Previously Presented) The method of Claim 20, wherein said anti-CD80 antibody competes for binding to CD80 antigen with antibody 7C10, produced by a hybridoma assigned ATCC accession no. HB-12117, or antibody 16C10, produced by a hybridoma assigned ATCC accession no. HB-12119.

35. (Previously Presented) The method of Claim 20, wherein said anti-CD80 antibody is a chimeric antibody comprising variable regions of antibody 7C10, produced by a hybridoma assigned ATCC accession no. HB-12117, or antibody 16C10, produced by a hybridoma assigned ATCC accession no. HB-12119.

Anderson et al. - U.S. Patent Appl. No. 09/576,424

36. (Previously Presented) The method of Claim 35, wherein said chimeric anti-CD80 antibody comprises a human constant region selected from the group consisting of human gamma 1 constant region, human gamma 4 constant region, and human gamma 4 PE constant region.

37. (Previously Presented) The method of Claim 35, wherein the light chain of said anti-CD80 antibody has the amino acid sequence shown in Fig. 3a (SEQ ID NO:1) and the heavy chain of said anti-CD80 antibody has the amino acid sequence shown in Figs. 3b and 3c (SEQ ID NO:3).

38. (Previously Presented) The method of Claim 35, wherein the light chain of said anti-CD80 antibody has the amino acid sequence shown in Fig. 5a (SEQ ID NO:9) and the heavy chain of said anti-CD80 antibody has the amino acid sequence shown in Figs. 5b and 5c (SEQ ID NO:11).

39. (Previously Presented) The method of Claim 36, wherein said chimeric anti-CD80 antibody comprises variable regions of antibody 16C10, produced by a hybridoma assigned ATCC accession no. HB-12119, and a human gamma 1 constant region.

40. (Previously Presented) The method of Claim 11, comprising administering a CD80-binding fragment of a monoclonal antibody that binds specifically to CD80 antigen without inhibiting the binding of CD80 antigen to CTLA-4.

41. (Previously Presented) The method of Claim 40, wherein said CD80-binding antibody fragment is selected from the group consisting of Fab, F(ab')₂, and Fv.

42. (Previously Presented) The method of Claim 40, wherein said CD80-binding antibody fragment competes for binding to CD80 antigen with antibody 7C10, produced by a hybridoma assigned ATCC accession no. HB-12117, or antibody 16C10, produced by a hybridoma assigned ATCC accession no. HB-12119.

43. (Previously Presented) The method of Claim 40, wherein said CD80-binding antibody fragment comprises variable regions of an Old World monkey antibody.

44. (Previously Presented) The method of Claim 43, wherein said CD80-binding antibody fragment comprises variable regions of antibody 7C10, produced by a hybridoma assigned ATCC accession no. HB-12117, or antibody 16C10, produced by a hybridoma assigned ATCC accession no. HB-12119.

Anderson et al. - U.S. Patent Appl. No. 09/576,424

45. (Previously Presented) The method of Claim 27, wherein said anti-CD80 antibody competes for binding to CD80 antigen with antibody 7C10, produced by a hybridoma assigned ATCC accession no. HB-12117, or antibody 16C10, produced by a hybridoma assigned ATCC accession no. HB-12119.

46. (Previously Presented) The method of Claim 29, wherein said chimeric anti-CD80 antibody comprises variable regions of antibody 7C10, produced by a hybridoma assigned ATCC accession no. HB-12117, or antibody 16C10, produced by a hybridoma assigned ATCC accession no. HB-12119.

47. (Previously Presented) The method of Claim 46, wherein said chimeric anti-CD80 antibody comprises a human constant region selected from the group consisting of human gamma 1 constant region, human gamma 4 constant region, and human gamma 4 PE constant region.

48. (Previously Presented) The method of Claim 46, wherein the light chain of said anti-CD80 antibody has the amino acid sequence shown in Fig. 3a (SEQ ID NO:1) and the heavy chain of said anti-CD80 antibody has the amino acid sequence shown in Figs. 3b and 3c (SEQ ID NO:3).

49. (Previously Presented) The method of Claim 46, wherein the light chain of said anti-CD80 antibody has the amino acid sequence shown in Fig. 5a (SEQ ID NO:9) and the heavy chain of said anti-CD80 antibody has the amino acid sequence shown in Figs. 5b and 5c (SEQ ID NO:11).

50. (Previously Presented) The method of Claim 47, wherein said anti-CD80 antibody comprises variable regions of antibody 16C10, produced by a hybridoma assigned ATCC accession no. HB-12119, and a human gamma 1 constant region.

51. (Previously Presented) The method of Claim 27, comprising administering a CD80-binding fragment of a monoclonal antibody that does not inhibit the CD80/CTLA-4 binding interaction.

52. (Previously Presented) The method of Claim 51, wherein said CD80-binding antibody fragment is selected from the group consisting of Fab, F(ab')₂, and Fv.

53. (Previously Presented) The method of Claim 51, wherein said CD80-binding antibody fragment competes for binding to CD80 antigen with antibody 7C10, produced by a

Anderson et al. - U.S. Patent Appt. No. 09/576,424

hybridoma assigned ATCC accession no. HB-12117, or antibody 16C10, produced by a hybridoma assigned ATCC accession no. HB-12119.

54. (Previously Presented) The method of Claim 51, wherein said CD80-binding antibody fragment comprises variable regions of an Old World monkey antibody.

55. (Previously Presented) The method of Claim 54, wherein said CD80-binding antibody fragment comprises variable regions of antibody 7C10, produced by a hybridoma assigned ATCC accession no. HB-12117, or antibody 16C10, produced by a hybridoma assigned ATCC accession no. HB-12119.